Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NovoCure Limited - Ordinary Shares (NQ:NVCR)

13.44 +2.94 (+28.00%)
Streaming Delayed Price Updated: 10:07 AM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about NovoCure Limited - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma
From Novocure
Via Business Wire
News headline image
FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
From Novocure
Via Business Wire
News headline image
Novocure Appoints Christoph Brackmann as Chief Financial Officer
From Novocure
Via Business Wire
News headline image
Novocure Reports Third Quarter 2024 Financial Results
From Novocure
Via Business Wire
NovoCure Ltd. (NASDAQ: NVCR) Leading the Way in Thursday Trading Based on Percentage Gain
Via Investor Brand Network
News headline image
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
News headline image
Novocure to Report Third Quarter 2024 Financial Results
From Novocure
Via Business Wire
News headline image
Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy
From Novocure
Via Business Wire
News headline image
Novocure Announces Planned CEO Transition
From Novocure
Via Business Wire
News headline image
Novocure to Participate in 2024 Wells Fargo Healthcare Conference
From Novocure
Via Business Wire
News headline image
Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer
From Novocure
Via Business Wire
News headline image
Novocure Reports Second Quarter 2024 Financial Results
From Novocure
Via Business Wire
News headline image
Novocure to Report Second Quarter 2024 Financial Results
From Novocure
Via Business Wire
News headline image
METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
From Novocure
Via Business Wire
News headline image
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
From Novocure
Via Business Wire
News headline image
Novocure Reports First Quarter 2024 Financial Results
From Novocure
Via Business Wire
News headline image
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
From Novocure
Via Business Wire
News headline image
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
From Novocure
Via Business Wire
News headline image
Novocure to Report First Quarter 2024 Financial Results
From Novocure
Via Business Wire
News headline image
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
News headline image
INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
From Novocure
Via Business Wire
News headline image
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
From Novocure
Via Business Wire
News headline image
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
News headline image
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
From Novocure
Via Business Wire
News headline image
Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update
From Novocure
Via Business Wire
News headline image
Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer
From Novocure
Via Business Wire
News headline image
Novocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference
From Novocure
Via Business Wire
News headline image
Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability
From Novocure
Via Business Wire
News headline image
Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference
From Novocure
Via Business Wire
News headline image
Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting
From Novocure
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.